Product Highlight - Rexulti
REXULTI®, a balanced treatment with short- and long-term efficacy for schizophrenia in adult 1,2
• REXULTI® demonstrated significant improvement in PANSS score in patients with acute schizophrenia 1
• 86.5% of patients remained relapse-free in a 52-week study2
• REXULTI® maintained improvements in general functioning as measured by GAF2
PANSS = Positive And Negative Syndrome Scale; GAF = Global Assessment of Functioning
1. Kane JM, Skuban A, Ouyang J et al. Schizophr Res. 2015 May;164(1-3):127-35.
2. Fleischhacker WW., Hobart M., Ouyang J. et al. Int J Neuropsychopharmacol. 2017 Jan 1; 20(1): 11–21.